Plureon has entered into an agreement with BD (Becton, Dickinson & Company) in the field of diabetes research and development using Plureon’s platform stem cell technology. BD will sponsor Plureon's research efforts for up to three years and will be responsible for further development of the technology. Plureon has retained rights to provide future manufacturing and medical education support to BD.
The Juvenile Diabetes Research Foundation (JDRF),
the world’s largest charitable funder of type 1 diabetes research, is
partnering with Plureon Corporation through JDRF's Industry Discovery and
Development Partnership Program. JDRF is providing two years of funds
for research aimed at generating insulin-producing beta-cells that may be
effective in the treatment of type 1 diabetes from pluripotent adult stem
cells.
Plureon has entered into multiple research agreements with the Wake Forest Institute for Regenerative Medicine ("WFIRM"), part of Wake Forest University Health Sciences, to conduct research related to Plureon technologies.
Plureon has received an STTR grant from the National Institutes of Health's National Institute of Diabetes & Digestive & Kidney Diseases to advance Plureon's technology in the field of diabetes. The grant provides $1 million in funding over two years, and may be extended for another three years thereafter at a higher funding level.
Plureon has been awarded Phase 1 and Phase 2 SBIR grants from the US Army to develop a keratin bioceramic antibiotic putty for bone regeneration. The technology has significant benefits over existing technologies in treating battlefield wounds, and has wide potential application in civilian markets as well.
Plureon has entered into an agreement with Cryo-Cell International, Inc. (OTC Bulletin Board: CCEL),
one of the world’s largest private cord blood banks, to offer expectant parents the opportunity to collect and preserve not only umbilical cord blood but also Plureon Stem Cells at the birth of their children.
Plureon has licensed from Children's Hospital Boston (a Harvard Medical School teaching affiliate) the exclusive worldwide rights to its patents pertaining to a novel type of stem cell discovered at the hospital's Laboratory for Cell Therapy and Tissue Engineering (PCT US02/36966).
